Table 2 Relationship between expression of UCA1 expression and clinicopathological characteristics in patients with LUAD. N(%)
From: Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma
Group | Total (n = 433) | UCA1 | P value | |
|---|---|---|---|---|
High expression | Low expression | |||
Gender | 0.229 | |||
Male | 198 | 93 (46.97) | 105 (53.03) | |
Female | 235 | 124 (52.77) | 111 (47.23) | |
Age (year) | 0.598 | |||
> 65 | 224 | 115 (51.34) | 109 (48.66) | |
≤ 65 | 209 | 102 (48.80) | 107 (51.20) | |
N stage | ||||
N0 | 281 | 142 (50.53) | 139 (49.47) | 0.706 |
N1–3 | 142 | 69 (48.59) | 73 (51.41) | |
NXa | 10 | 6 (60.00) | 4 (40.00) | |
T stage | ||||
T1–2 | 376 | 185 (49.20) | 191 (50.80) | 0.383 |
T3–4 | 54 | 30 (55.56) | 24 (44.44) | |
TXa | 3 | 2 (66.67) | 1 (33.33) | |
M stage | ||||
M0 | 286 | 137 (47.90) | 149 (52.10) | 0.019* |
M1 | 20 | 15 (75.00) | 5 (25.00) | |
MXa | 127 | 65 (51.18) | 62 (48.82) | |
Clinical stage | 0.046* | |||
I, II | 344 | 164 (47.67) | 180 (52.32) | |
III, IV | 89 | 53 (59.55) | 36 (40.45) | |
Smoking | 0.434 | |||
No | 66 | 36 (54.55) | 30 (45.45) | |
Yes | 277 | 181 (49.32) | 186 (50.68) | |
Tumor location | 0.217 | |||
Superior lobe of left lung | 108 | 61 (56.48) | 47 (43.52) | |
Inferior lobe of left lung | 65 | 28 (43.08) | 37 (56.92) | |
Superior lobe of right lung | 159 | 72 (45.28) | 87 (54.72) | |
Middle lobe of right lung | 17 | 10 (58.82) | 7 (41.18) | |
Inferior lobe of right lung | 84 | 46 (54.76) | 38 (45.23) | |